Urogen Pharma (NASDAQ:URGN) Given “Buy” Rating at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Urogen Pharma (NASDAQ:URGN) in a research report released on Friday,Benzinga reports. They currently have a $25.00 price target on the stock.

Several other research analysts have also recently weighed in on URGN. Piper Sandler started coverage on Urogen Pharma in a report on Monday, August 18th. They set an “overweight” rating and a $36.00 target price on the stock. Oppenheimer set a $31.00 target price on Urogen Pharma and gave the stock a “buy” rating in a report on Friday, June 13th. Guggenheim restated a “buy” rating and set a $30.00 target price (up from $15.00) on shares of Urogen Pharma in a report on Friday, June 13th. HC Wainwright lowered their target price on Urogen Pharma from $50.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, August 11th. Finally, Wall Street Zen raised shares of Urogen Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, September 13th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Urogen Pharma has an average rating of “Moderate Buy” and an average price target of $32.00.

Urogen Pharma Price Performance

Shares of Urogen Pharma stock opened at $17.40 on Friday. The stock has a market cap of $804.99 million, a P/E ratio of -5.24 and a beta of 1.00. The stock’s 50 day simple moving average is $19.00 and its 200-day simple moving average is $13.67. Urogen Pharma has a 1-year low of $3.42 and a 1-year high of $21.71.

Urogen Pharma (NASDAQ:URGN) last issued its earnings results on Thursday, August 7th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.23). The company had revenue of $24.22 million for the quarter, compared to analyst estimates of $23.06 million. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 164.44%. As a group, research analysts expect that Urogen Pharma will post -3.12 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Mark Schoenberg sold 10,000 shares of the business’s stock in a transaction on Monday, August 11th. The shares were sold at an average price of $17.69, for a total transaction of $176,900.00. Following the completion of the transaction, the insider owned 148,229 shares in the company, valued at approximately $2,622,171.01. The trade was a 6.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, General Counsel Jason Drew Smith sold 7,522 shares of the business’s stock in a transaction on Monday, July 28th. The stock was sold at an average price of $19.14, for a total transaction of $143,971.08. Following the transaction, the general counsel owned 41,492 shares of the company’s stock, valued at approximately $794,156.88. The trade was a 15.35% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 25,062 shares of company stock valued at $465,115. Insiders own 4.70% of the company’s stock.

Hedge Funds Weigh In On Urogen Pharma

Hedge funds have recently made changes to their positions in the company. RA Capital Management L.P. acquired a new stake in shares of Urogen Pharma during the first quarter worth about $35,461,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Urogen Pharma by 216.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company’s stock worth $48,227,000 after buying an additional 2,983,368 shares during the period. Soleus Capital Management L.P. acquired a new position in Urogen Pharma during the second quarter worth approximately $29,934,000. SG Americas Securities LLC increased its position in Urogen Pharma by 607.1% during the second quarter. SG Americas Securities LLC now owns 1,149,081 shares of the company’s stock worth $15,742,000 after buying an additional 986,567 shares during the period. Finally, Vestal Point Capital LP increased its position in Urogen Pharma by 32.1% during the first quarter. Vestal Point Capital LP now owns 2,152,957 shares of the company’s stock worth $23,812,000 after buying an additional 522,957 shares during the period. Hedge funds and other institutional investors own 91.29% of the company’s stock.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.